Mecasermin Rinfabate

Mecasermin Rinfabate Uses, Dosage, Side Effects, Food Interaction and all others data.

Mecasermin Rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH). Mecasermin Rinfabate is similar to Mecasermin in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin Rinfabate however, is already bound to recombinant DNA origin insulin-like growth factor binding protein 3 (IGFBP-3). The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent.Mecasermin Rinfabate promotes vertical growth in pediatric patients in a similar fashion to Mecasermin.

Mecasermin is a biosynthetic (recombinant DNA origin) form of human insulin-like growth factor 1 (IGF-1) designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normalized statural growth. Growth hormones (GH) bind to growth hormone receptors (GHR) in the liver and other tissues, which stimulates the synthesis of IGF-1. In target tissues, IGF-1 activates the IGF-1 receptor, resulting in intracellular signals that stimulate growth . Although many actions of the GH are mediated through IGF-1, the precise roles of GH and IGF-1 have not been fully elucidated. Patients with severe primary IGF-1 deficiency (Primary IGFD) fail to produce adequate levels of IGF-1, due to disruption of the GH pathway used to promote IGF-1 release (possible GH pathway disruptions include mutations in the GHR, post-GHR signaling pathway, and IGF-1 gene defects.

Mecasermin Rinfabate
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Mecasermin Rinfabate
Generic	Mecasermin rinfabate
Mecasermin rinfabate Other Names	Mecasermin rinfabate, Mecasermin rinfabate recombinant
Type
Protein binding	Mecasermin rinfabate is formulated as two proteins (IGF-1 and IGFBP-3) already bound together in the same way they are naturally found in the human body. This increases the serum half life of Mecasermin.
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Mecasermin Rinfabate was approved for treatment of severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH). Severe primary IGF-1 deficiency is defined by:

A) height standard deviation (SD) score less than or equal to 3 SD below normal

B) basal IGF-1 SD score less than or equal to 3 SD below normal

C) normal or above normal levels of growth hormone

In 2007, Insmed (Mecasermin Rinfabate's manufacturer) made an agreement with Tercica (Mecasermin's manufacturer) that Mecasermin would no longer be available for this indication but could be developed for non short stature conditions such as severe insulin resistance, myotonic muscular dystrophy, and HIV associated adipose redistribution syndrome.

Mecasermin Rinfabate is also used to associated treatment for these conditions: Growth Hormone Gene Deletion, Primary Insulin-like Growth Factor-1 Deficiency

How Mecasermin Rinfabate works

Mecasermin Rinfabate supplies recombinant-DNA-origin IGF-1 (rhIGF-1) bound to recombinant-DNA-origin IGFBP-3. 80% of IGF-1 is naturally bound to IGFBP-3 so the binding of rhIGF-1 to rhIGFBP-3 increases the half life of rhIGF-1 compared to Mecasermin. rhIGF-1 binds to the Type I IGF-1 receptor. This receptor exerts intra-cellular signaling activity in a number of processes involved in statural growth, including mitogenesis in multiple tissue types, chondrocyte growth and division along cartilage growth plates, and increases in organ growth.

Toxicity

Studies on carcinogenicity, genotoxicity, animal fertility, fetal development, excretion in breast milk, and use in patients over 65 years have not been performed. Use in pregnant, breast feeding, or geriatric populations should be avoided as there is a lack of safety data. Animal reproductive toxicity studies have shown increased incidence of abortion, post implantation loss, fewer viable fetuses, and an increase in fetal skeletal abnormalities. Insulin-like growth factor 1 (IGF-1) without insulin-like growth factor binding protein 3 (IGFBP-3) has been shown to not be mutagenic according to the Ames test and have no affect on fertility in rats given 7 times the maximum human recommended dose based on body surface area. No studies have been performed in patients with impaired renal or hepatic function however these impairments are not expected to significantly affect the pharmacokinetics of Mecasermin Rinfabate.

Food Interaction

Take at the same time every day.

Volume of Distribution

Approximately 1000mL/kg.

Elimination Route

There is little published data on the pharmacokinetics of Mecasermin Rinfabate. Mecasermin Rinfabate is injected subcutaneously and distributes rapidly throughout the body, especially in well vascularized tissue.